hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06340919 id: 1406014978-241 briefTitle: Hearing Aid Algorithms for Sudden Sounds overallStatus: ENROLLING_BY_INVITATION date: 2024-02-21 date: 2024-09-30 date: 2025-05-31 date: 2024-04-02 date: 2024-04-02 name: Purdue University class: OTHER name: Oticon briefSummary: This study explores the impact of hearing aid settings for managing sudden sounds on speech comprehension and recall in individuals with hearing loss. Participants will undergo a comprehensive audiological evaluation, case history, and cognitive assessments. Subsequently, they will participate in listening experiments designed to measure sentence recognition, storage, and retrieval under various sudden sound reduction conditions recorded through a hearing aid. The experiment will be complemented by subjective preference ratings to identify participant comfort and listening clarity associated with different sudden sound reduction settings. conditions: Hearing Loss studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: BASIC_SCIENCE masking: SINGLE whoMasked: PARTICIPANT count: 60 type: ESTIMATED name: Sudden Sound Reduction Setting measure: Speech recognition measure: Recall measure: Preference sex: ALL minimumAge: 18 Years maximumAge: 79 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Purdue University city: West Lafayette state: Indiana zip: 47907 country: United States lat: 40.42587 lon: -86.90807 hasResults: False
nctId: NCT06340893 id: 76117 briefTitle: Exercise Training in Children With Communication Impairments overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2024-08-31 date: 2024-08-31 date: 2024-04-02 date: 2024-04-02 name: Marquette University class: OTHER name: University of Arizona briefSummary: This clinical trial study has two goals. The first goal is to establish fitness levels, participation in physical activities, and fine/gross motor abilities for children with development language disorder (DLD). DLD occurs in 1/13 children and children with DLD often have poorer fine/gross motor skills than those with typical development. The second goal is to determine whether physical exercise helps children with DLD and typical development to learn better and improve fitness and fine/gross motor abilities more than participating in restful play activities.
Researchers will compare changes in learning tasks and fitness levels for children (DLD and typically developing) who participated in the exercise program vs. restful play program. conditions: Developmental Language Disorder studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Participants will be randomly assigned to the exercise intervention group or to the restful play (sham) condition. primaryPurpose: TREATMENT masking: SINGLE maskingDescription: Outcome assessors will be blinded to group and will be different to those conducting the interventions. whoMasked: OUTCOMES_ASSESSOR count: 40 type: ESTIMATED name: Exercise name: Restful Play measure: Changes to cognitive-linguistic performance: Word learning accuracy (% correct) measure: Changes to cognitive-linguistic performance: Reaction time on the Serial Reaction Time task (milliseconds) measure: Fitness: Maximum oxygen consumption (VO2 max) (ml/kg/min) measure: Motor Performance (scaled scores) measure: Enjoyment of Intervention sex: ALL minimumAge: 6 Years maximumAge: 8 Years stdAges: CHILD facility: Marquette U city: Milwaukee state: Wisconsin zip: 53201 country: United States name: Jenya Iuzzini-Seigel, PhD role: CONTACT phone: 585-489-4683 email: jenya.iuzzini-seigel@marquette.edu lat: 43.0389 lon: -87.90647 hasResults: False
nctId: NCT06340880 id: SAPB briefTitle: Serratus Anterior Plane Block, Ultrasound vs Anatomical Landmark Guided. overallStatus: RECRUITING date: 2024-03 date: 2024-05 date: 2024-05 date: 2024-04-02 date: 2024-04-02 name: Menoufia University class: OTHER briefSummary: This prospective, double-blinded randomized controlled trial aims to compare the efficacy of the serratus anterior plane block (SAPB) ultrasound guided versus anatomical landmark guided for gynecomastia surgery. And to detect if the anatomical landmark technique is inferior or not to the ultrasound guided technique. We hypothesize that anatomical landmark guided SAPB is not inferior to ultrasound guided SAPB. conditions: Serratus Anterior Plane Block studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 40 type: ESTIMATED name: Serratus anterior plane block measure: visual numerical rating score (NRS) measure: first call of analgesia measure: incidence of complications measure: patient satisfaction sex: MALE minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT facility: Menoufia University Hospitals status: RECRUITING city: Shibīn Al Kawm state: Menoufia country: Egypt name: Menoufia U Hospitals role: CONTACT phone: +20482228303 email: info@menofia.edu.eg lat: 30.55258 lon: 31.00904 hasResults: False
nctId: NCT06340867 id: 30723 briefTitle: Intraoral Scanner With and Without Orthodontic Brackets overallStatus: ACTIVE_NOT_RECRUITING date: 2023-09-01 date: 2024-03-24 date: 2024-04-01 date: 2024-04-02 date: 2024-04-02 name: Cairo University class: OTHER briefSummary: this study aim to evaluate the effect of two different intraoral scanners on the scanning Quality and Time in Patients With/Without Orthodontic Brackets conditions: Intra-oral Scanner conditions: Adolescent Behavior studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: CROSS_SECTIONAL count: 10 type: ACTUAL name: CEREC primescan intra-oral scanner measure: The effect of the different scanning techniques on the scanning quality and time measure: The effect of the bracket presence on the scanning quality sex: ALL minimumAge: 14 Years maximumAge: 35 Years stdAges: CHILD stdAges: ADULT facility: Faculty of Dentistry, Cairo university city: Cairo country: Egypt lat: 30.06263 lon: 31.24967 hasResults: False
nctId: NCT06340841 id: LEMURS SSI 24 briefTitle: LEMURS SSI: Evaluation of Behavioral Incentives acronym: LEMURSSI overallStatus: RECRUITING date: 2024-02-12 date: 2024-05-31 date: 2028-05-31 date: 2024-04-02 date: 2024-04-02 name: University of Vermont class: OTHER briefSummary: The goal of this substudy is to determine if a brief single-session-intervention (SSI) coupled with different incentive strategies to support engaging in wellness-related activities. conditions: Incentives studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: FACTORIAL interventionModelDescription: Participants will be randomized to one of four incentive conditions and receive rewards based on their completion of such activities. There are two main factors (Recipient x Restoration) that will create four distinct groups. primaryPurpose: HEALTH_SERVICES_RESEARCH masking: NONE count: 200 type: ESTIMATED name: Personal Incentives name: Personal Restorative Incentives name: Charity Incentives name: Charity Restorative Incentives measure: Activity Completion measure: Depression, Anxiety, Stress Scale - 21 measure: Depression, Anxiety, Stress Scale - 21 measure: Depression, Anxiety, Stress Scale - 21 measure: Warwick-Edinburgh Mental Well-being Scale measure: Oura Ring Sleep Index sex: ALL minimumAge: 18 Years maximumAge: 20 Years stdAges: ADULT facility: University of Vermont status: RECRUITING city: Burlington state: Vermont zip: 05405 country: United States name: Matthew Price, PhD role: CONTACT phone: 802-656-9196 email: Matthew.Price@uvm.edu lat: 44.47588 lon: -73.21207 hasResults: False
nctId: NCT06340828 id: 2023-KY-186-01 briefTitle: Washed Microbiota Transplantation Alleviates Diabetic Gastrointestinal Motility Disorders: an Efficacy and Safety Study overallStatus: NOT_YET_RECRUITING date: 2024-04-20 date: 2027-07-20 date: 2027-07-20 date: 2024-04-02 date: 2024-04-03 name: The Second Hospital of Nanjing Medical University class: OTHER briefSummary: The goal of this clinical trial is to learn about effectiveness and safety of washing microbiota transplantation in diabetic gastrointestinal motility disorders participant population. The main questions it aims to answer are:
Participants will be collected fasting venous blood and random stool samples before treatment and at week 12 post-treatment, conducting scale assessments before treatment and at weeks 1, 4, and 12 post-treatment. conditions: Diabetic Gastroparesis conditions: Diabetic Gastropathy conditions: Diabetic Gastroenteropathy conditions: Diabetic Gastroparesis Associated With Type 2 Diabetes Mellitus studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 40 type: ESTIMATED name: Washing Microbiota Transplantation measure: Gastrointestinal Symptom Rating Scale measure: Gut Microbiome Sequencing measure: Gastroparesis Cardinal Symptom Index measure: Composite Autonomic Symptom Score 31 measure: Gastrointestinal Motility measure: Heart Rate Variability measure: Serum Metabolites sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: The Second Affiliated Hospital of Nanjing Medical University city: Nanjing state: Jiangsu zip: 210000 country: China name: Dafa Ding, Professor role: CONTACT phone: +8615850514014 email: dingdafa@njmu.edu.cn lat: 32.06167 lon: 118.77778 hasResults: False
nctId: NCT06340815 id: VAR-2022-02 briefTitle: Varian ProBeam Proton Therapy System Clinical Trial (Shandong) overallStatus: COMPLETED date: 2022-07-20 date: 2023-03-08 date: 2023-03-10 date: 2024-04-02 date: 2024-04-02 name: Varian, a Siemens Healthineers Company class: INDUSTRY briefSummary: This study is prospective, single-center, single-arm objective performance criteria.
This trial will be conducted with a total of 47 subjects enrolled. All of subjects will be treated with radiation therapy using the medical device Varian ProBeam Proton Therapy System (ProBeam), aim to compare the data with objective performance criteria (OPC) to evaluate the effectiveness and safety of ProBeam radiotherapy system for oncology patients, providing a clinical basis for the medical device registration. conditions: Tumor, Solid studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: a clinical study of prospective, single-arm objective performance criteria primaryPurpose: TREATMENT masking: NONE count: 47 type: ACTUAL name: Radiation: Proton Therapy System (ProBeam) measure: Effectiveness evaluation: Local tumor control rate at 90 days after the proton radiation treatment completion measure: Safety evaluation: Incidence of Acute radiation injury measure: Safety evaluation: Incidence of Adverse Events based on CTCAE 5.0 criteria sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Sophia Shao city: Shanghai zip: 230001 country: China lat: 31.22222 lon: 121.45806 hasResults: False
nctId: NCT06340802 id: SYG001 briefTitle: A First in hUman Study for Resistant Epilepsy With the Vagus Nerve stimulatiOn Device by syneRgia medicAl acronym: AURORA overallStatus: NOT_YET_RECRUITING date: 2024-06 date: 2025-03 date: 2026-12 date: 2024-04-02 date: 2024-04-02 name: Synergia Medical class: INDUSTRY briefSummary: This is an open label, single arm, interventional, prospective first in human study, designed to evaluate the safety of the NAO.VNS SYSTEM. conditions: Drug Resistant Epilepsy studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: OTHER masking: NONE count: 10 type: ESTIMATED name: VNS Treatment measure: Treatment emergent adverse events measure: Procedure and/or device related adverse events measure: Device-related treatment emergent adverse events measure: Device deficiencies measure: Procedural Success measure: Change in seizure frequency measure: Proportion of responders measure: Change in seizure severity measure: Change in quality of life measure: Changed in mood measure: Usability measure: Exploratory Endpoints sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06340776 id: 81321 briefTitle: The Effects of Acupressure on Pain, and Gastrointestinal Functions in Women With Hysterectomy overallStatus: COMPLETED date: 2021-08-15 date: 2023-06-20 date: 2023-09-28 date: 2024-04-02 date: 2024-04-25 name: Istanbul Medipol University Hospital class: OTHER briefSummary: Aim This randomized controlled trial was conducted to evaluate the effect of acupressure application on gastrointestinal functions and pain after abdominal hysterectomy.
Materials and methods After undergoing hysterectomy, 39 women were randomised into acupressure (n=19), and control groups (n=20). Women in the acupressure group received acupressure on the mide meridian (ST36), the heart meridian (HT7), large intestine meridian (LI4), intersection of the spleen, liver and kidney meridians 6(SP6) and pericardium meridian (PC6) acupoints 30 min after admission to the clinic, for a period of 15 min, whereas those in the sham group received acupressure on locations 1-1.5 cm away from these points. The control group received standard treatment. The patient information form, Visual analog scale, the Rhodes Index of Nausea, Vomiting and Retching, and daily follow-up form were used for data collection. conditions: Pain Management conditions: Hysterectomy conditions: Vomiting studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Acupressure groupThose who received acupressure application were called the experimental group, and patients who received routine post-operative care were called the control group. Acupressure application was applied to the experimental group at the third and twenty-fourth hours after surgery.
Control group:The control group was evaluated for two days without any application. primaryPurpose: SUPPORTIVE_CARE masking: TRIPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: OUTCOMES_ASSESSOR count: 60 type: ACTUAL name: Acupressure measure: the score of nausea, vomiting and retching experiences measure: gas output and stool formation of the participants measure: postoperative pain measure: Systolic Blood pressure measure: Heart rate measure: Diastolic blood pressure sex: FEMALE minimumAge: 35 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Yeliz Yildirim Varişoğlu city: Istanbul state: Beykoz zip: 34413 country: Turkey lat: 41.01384 lon: 28.94966 hasResults: False
nctId: NCT06340763 id: ABT-CIP-10466 id: CRD_1058 type: OTHER domain: Abbott briefTitle: JETi Hong Kong Post Market Study (PMS) overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2025-02 date: 2025-02 date: 2024-04-01 date: 2024-04-04 name: Abbott Medical Devices class: INDUSTRY briefSummary: The JETi Hong Kong PMS is a prospective, single-arm, multicenter study to collect real-world data on the safety, performance, and clinical benefits of the JETi System for the treatment of acute and subacute thrombosis in the lower extremity peripheral vasculature. This is a post-market study that will register approximately 20 subjects at approximately 5 centers in Hong Kong. Subjects participating in this study will be followed for up to 30 days after the JETi procedure. conditions: Peripheral Artery Thrombosis conditions: Peripheral Venous Thrombosis studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 20 type: ESTIMATED name: JETi Hydrodynamic Thrombectomy System measure: For Arterial Subjects: Clot removal grade for each JETi-treated vessel measure: For Arterial Subjects: Composite of JETi-related major adverse events (MAEs) measure: For Venous Subjects: Percent of treated vessel(s) with ≥ 75% venous thrombus reduction via modified Marder score (limb basis). measure: For Venous Subjects: Composite of JETi-related major adverse events (MAEs) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Prince of Wales Hospital city: Hong Kong country: Hong Kong name: Guangming TAN, Prof. role: CONTACT phone: +852 3505 2211 name: Guangming TAN, Prof. role: PRINCIPAL_INVESTIGATOR lat: 22.27832 lon: 114.17469 hasResults: False
nctId: NCT06340750 id: LMY-920-003 briefTitle: BAFF CAR-T Cells (LMY-920) for Systemic Lupus Erythematosus overallStatus: NOT_YET_RECRUITING date: 2024-04-15 date: 2025-10-15 date: 2026-04-15 date: 2024-04-01 date: 2024-04-01 name: Luminary Therapeutics class: INDUSTRY name: Nationwide Children briefSummary: This phase 1 study seeks to examine the safety and recommended phase 2 dose (RP2D) of BAFF-ligand CAR-T cells (LMY-920) in adult patients with refractory systemic lupus erythematosus (SLE). It is hypothesized that BAFF CAR-T cells will be safe and will improve SLE disease activity scores. conditions: Systemic Lupus Erythematosus studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SEQUENTIAL primaryPurpose: TREATMENT masking: NONE count: 18 type: ESTIMATED name: LMY-920 measure: Safety of the Treatment measure: Recommended Phase 2 Dose (RP2D) measure: Efficacy of the Treatment: SELENA-SLEDAI measure: Efficacy of the Treatment: BILAG measure: Efficacy of the Treatment: PGA sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06340737 id: IRB-73394 briefTitle: AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas overallStatus: RECRUITING date: 2024-03-29 date: 2031-04 date: 2031-04 date: 2024-04-01 date: 2024-04-03 name: Stanford University class: OTHER name: The Leukemia and Lymphoma Society briefSummary: This is a non-randomized clinical trial to evaluate the safety and efficacy of CD22CART administered after lymphodepleting chemotherapy in adults with relapsed / refractory B Cell Lymphomas. All evaluable participants will be followed for overall survival (OS), progression free survival (PFS), and duration of response (DOR). An evaluable participant is one who completes leukapheresis, lymphodepleting chemotherapy and CART infusion. conditions: Follicular Lymphoma conditions: Mantle Cell Lymphoma conditions: Hairy Cell Leukemia conditions: Lymphoplasmacytic Lymphoma conditions: Burkitt Lymphoma conditions: Marginal Zone Lymphoma conditions: Waldenstrom Macroglobulinemia studyType: INTERVENTIONAL phases: PHASE1 allocation: NON_RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 120 type: ESTIMATED name: CD22CART Infusion measure: Determine the manufacturing feasibility of CD22 CART by assessing the target dose level and release specifications in each disease cohort. measure: Maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D) measure: Determine the overall response rate (ORR) in adults with follicular lymphoma (FL) and mantle cell lymphoma (MCL) measure: Evaluate Progression Free Survival (PFS) measure: Evaluate Overall Survival (OS) measure: Evaluate Duration of Response (DOR) measure: Assess the response rate in adults with relapsed/refractory Hairy cell leukemia (HCL), Lymphoplasmacytic lymphoma (Waldenstrom macroglobulemia) (WM), Burkitt lymphoma (BL), and Marginal Zone lymphoma (MZL). sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Stanford University status: RECRUITING city: Palo Alto state: California zip: 94304 country: United States name: Kelly Chyan role: CONTACT phone: 650-625-8130 email: kchyan@stanford.edu name: Matthew Frank, MD role: PRINCIPAL_INVESTIGATOR lat: 37.44188 lon: -122.14302 hasResults: False
nctId: NCT06340724 id: KY20240123-08 briefTitle: Banxiaxiexin Decoction Combined With Vonoprazan-Amoxicillin Dual Therapy in H.Pylori Eradication overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2024-10 date: 2025-03 date: 2024-04-01 date: 2024-04-01 name: Nanjing First Hospital, Nanjing Medical University class: OTHER briefSummary: Vonoprazan and high-dose amoxicillin dual therapy was used as a control group to evaluate the clinical effiency and safety of Banxiaxiexin decoction combined with vonoprazan and high-dose amoxicillin dual therapy in the treatment of helicobacter pylori infection complicated with functional dyspepsia,through a randomized controlled trail. conditions: Helicobacter Pylori Infection studyType: INTERVENTIONAL phases: EARLY_PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 100 type: ESTIMATED name: Vonoprazan name: Amoxicillin name: Banxiaxiexin decotion measure: Change from Baseline in functional dyspepsia symptoms at 6 weeks measure: Change in Traditional Chinese Medicine syndromes from Baseline to 6 weeks measure: Adverse reactions that occur after taking medication measure: Patients' drug compliance sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Nanjing First Hospitai city: Nanjing state: Jiangsu zip: 210006 country: China name: Wenjuan Wei, Doctorate role: CONTACT phone: +8618851009006 email: wjwei.hf@hotmail.com lat: 32.06167 lon: 118.77778 hasResults: False
nctId: NCT06340711 id: 23-06026219 briefTitle: Study of Suratadenoturev (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2026-04 date: 2028-04 date: 2024-04-01 date: 2024-04-01 name: Weill Medical College of Cornell University class: OTHER name: Merck Sharp & Dohme LLC name: Oncolys BioPharma Inc briefSummary: The goal of this study is to learn about of the research study drug, telomelysin (OBP-301), in combination with pembrolizumab in advanced or metastatic gastric or gastroesophageal junction (GEJ) cancer. The main question it aims to answer is whether this combination is safe and effective in this type of cancer.
Participants will receive 5 injections of OBP-301, approximately every 2 weeks. OBP-301 will be injected directly into the tumor during an esophagogastroduodenoscopy (EGD). At the same time as the injection, a tumor biopsy will be taken. Participants will also receive pembrolizumab infusions every 6 weeks until disease progression or for a maximum of two years. Pembrolizumab infusions will occur on different days than OBP-301 injections. conditions: Esophageal Adenocarcinoma conditions: Gastric Adenocarcinoma conditions: Gastroesophageal Junction Adenocarcinoma studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 27 type: ESTIMATED name: OBP-301 name: Pembrolizumab measure: Overall response rate as assessed by the RECIST v1.1 measure: Number of serious adverse events (SAEs) tabulated by severity and classification per the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0 measure: Number of adverse events (AEs) tabulated by severity and classification per the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0 measure: Disease control rate (DCR) measure: Duration of response (DoR) measure: Overall Survival (OS) measure: Progression free survival (PFS) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Weill Cornell Medicine/NewYork-Presbyterian Hospital city: New York state: New York zip: 10065 country: United States name: Casey Owens role: CONTACT email: cdo4001@med.cornell.edu name: Manish Shah, M.D. role: PRINCIPAL_INVESTIGATOR lat: 40.71427 lon: -74.00597 hasResults: False
nctId: NCT06340698 id: GRF-11606221 briefTitle: An RCT to Improve HRQoL of HIV+ Mothers and Children overallStatus: RECRUITING date: 2024-02-20 date: 2024-10 date: 2025-02 date: 2024-04-01 date: 2024-04-01 name: City University of Hong Kong class: OTHER briefSummary: The goal of this randomized controlled trial is to test the effectiveness of a resilience intervention and an adherence intervention in improving health-related quality of life (HRQoL) among perinatally infected HIV positive children and their HIV positive mothers in China.